Celularity (CELU) Competitors $3.12 -0.16 (-4.88%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$3.13 +0.01 (+0.32%) As of 08/1/2025 07:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CELU vs. BNTC, SGMT, AVIR, CRDF, MNPR, UPXI, MREO, LFCR, VOR, and AVTEShould you be buying Celularity stock or one of its competitors? The main competitors of Celularity include Benitec Biopharma (BNTC), Sagimet Biosciences (SGMT), Atea Pharmaceuticals (AVIR), Cardiff Oncology (CRDF), Monopar Therapeutics (MNPR), Upexi (UPXI), Mereo BioPharma Group (MREO), Lifecore Biomedical (LFCR), Vor Biopharma (VOR), and Aerovate Therapeutics (AVTE). These companies are all part of the "pharmaceutical products" industry. Celularity vs. Its Competitors Benitec Biopharma Sagimet Biosciences Atea Pharmaceuticals Cardiff Oncology Monopar Therapeutics Upexi Mereo BioPharma Group Lifecore Biomedical Vor Biopharma Aerovate Therapeutics Benitec Biopharma (NASDAQ:BNTC) and Celularity (NASDAQ:CELU) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, media sentiment, analyst recommendations, dividends and earnings. Do insiders and institutionals believe in BNTC or CELU? 52.2% of Benitec Biopharma shares are held by institutional investors. Comparatively, 19.0% of Celularity shares are held by institutional investors. 1.3% of Benitec Biopharma shares are held by insiders. Comparatively, 22.1% of Celularity shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Is BNTC or CELU more profitable? Benitec Biopharma has a net margin of 0.00% compared to Celularity's net margin of -106.77%. Benitec Biopharma's return on equity of -38.26% beat Celularity's return on equity.Company Net Margins Return on Equity Return on Assets Benitec BiopharmaN/A -38.26% -35.71% Celularity -106.77%-271.88%-42.82% Which has stronger valuation and earnings, BNTC or CELU? Benitec Biopharma has higher earnings, but lower revenue than Celularity. Benitec Biopharma is trading at a lower price-to-earnings ratio than Celularity, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBenitec Biopharma$80K3,596.25-$21.75M-$1.51-7.26Celularity$54.22M1.38-$57.89M-$2.65-1.18 Which has more volatility & risk, BNTC or CELU? Benitec Biopharma has a beta of 0.4, indicating that its share price is 60% less volatile than the S&P 500. Comparatively, Celularity has a beta of 0.79, indicating that its share price is 21% less volatile than the S&P 500. Does the media refer more to BNTC or CELU? In the previous week, Celularity had 1 more articles in the media than Benitec Biopharma. MarketBeat recorded 1 mentions for Celularity and 0 mentions for Benitec Biopharma. Benitec Biopharma's average media sentiment score of 1.16 beat Celularity's score of 0.34 indicating that Benitec Biopharma is being referred to more favorably in the media. Company Overall Sentiment Benitec Biopharma Positive Celularity Neutral Do analysts recommend BNTC or CELU? Benitec Biopharma currently has a consensus target price of $26.00, indicating a potential upside of 137.23%. Given Benitec Biopharma's stronger consensus rating and higher possible upside, analysts plainly believe Benitec Biopharma is more favorable than Celularity.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Benitec Biopharma 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13Celularity 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryBenitec Biopharma beats Celularity on 12 of the 17 factors compared between the two stocks. Get Celularity News Delivered to You Automatically Sign up to receive the latest news and ratings for CELU and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CELU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CELU vs. The Competition Export to ExcelMetricCelularityMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$78.55M$2.99B$5.48B$9.54BDividend YieldN/A2.43%4.73%4.09%P/E Ratio-1.1817.7428.8623.83Price / Sales1.38178.75371.4566.14Price / CashN/A41.9535.4557.96Price / Book8.438.508.265.54Net Income-$57.89M-$55.06M$3.25B$259.28M7 Day Performance5.41%-3.99%-3.75%-4.67%1 Month Performance53.69%9.58%4.27%4.37%1 Year Performance6.85%6.70%25.85%17.91% Celularity Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CELUCelularity0.2161 of 5 stars$3.12-4.9%N/A-1.0%$78.55M$54.22M-1.18220News CoverageUpcoming EarningsAnalyst UpgradeBNTCBenitec Biopharma1.5817 of 5 stars$11.18+1.3%$26.00+132.6%+30.0%$289.80MN/A-7.4020Positive NewsSGMTSagimet Biosciences2.9704 of 5 stars$8.83-6.2%$26.60+201.2%+137.1%$288.65M$2M-5.028Gap DownAVIRAtea Pharmaceuticals1.6961 of 5 stars$3.43+2.1%$6.00+74.9%-4.4%$287.55MN/A-2.0870News CoverageUpcoming EarningsCRDFCardiff Oncology1.7998 of 5 stars$3.91-8.6%$11.70+199.2%+14.3%$284.73M$680K-4.2520Trending NewsEarnings ReportInsider TradeOptions VolumeAnalyst RevisionGap UpMNPRMonopar Therapeutics1.9643 of 5 stars$46.43-0.1%$60.00+29.2%+1,074.0%$284.23MN/A-13.3410Upcoming EarningsUPXIUpexi3.7435 of 5 stars$8.15+9.0%$16.00+96.3%-32.3%$283.61M$26M0.00130Insider TradeGap DownHigh Trading VolumeMREOMereo BioPharma Group1.3859 of 5 stars$1.71-3.4%$7.20+321.1%-58.3%$281.43M$10M-24.4340High Trading VolumeLFCRLifecore Biomedical1.4616 of 5 stars$7.46-0.4%$8.00+7.2%+15.9%$277.32M$128.26M-5.14690News CoverageVORVor Biopharma0.5983 of 5 stars$2.05-7.2%N/AN/A$276.16MN/A-1.36140News CoverageShort Interest ↑Gap UpAVTEAerovate TherapeuticsN/A$9.47-0.4%N/A-88.5%$274.49MN/A-3.1720High Trading Volume Related Companies and Tools Related Companies BNTC Competitors SGMT Competitors AVIR Competitors CRDF Competitors MNPR Competitors UPXI Competitors MREO Competitors LFCR Competitors VOR Competitors AVTE Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CELU) was last updated on 8/2/2025 by MarketBeat.com Staff From Our Partners379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredDigital Dollar Alert: Protect Your Wealth Before It’s Too Late134 countries are developing Central Bank Digital Currencies — and the U.S. is quietly testing one. Experts...American Alternative | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | SponsoredTrump’s crypto advisor may have revealed the next big crypto opportunityWhile investors chase Bitcoin toward $100K, D.C. insiders are quietly loading up on something else. One of Tru...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Celularity, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Celularity With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.